A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors

Trial Details

  • 800 patients will be taking part in this study
  • Condition: Ulcerative Colitis
  • Intervention: Drug: etrozulimab Drug: placebo
  • Clinic: GI Research Institute Suite 770-1190 Hornby Street, Vancouver BC

Summary

This phase III, double blind, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab during induction and maintenance of remission in patients with moderately to severely active ulcerative colitis (UC) who are refractory to or intolerant of tumor necrosis factor (TNF) inhibitors.

Full Trial Details

Researchers

Dr. Brian Bressler

Brian bressler headshot for dt trial listings